News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Talon Therapeutics, Inc. Provides NDA Submission Timeline Update for Marqibo(R)
June 30, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SAN MATEO, Calif., June 30, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today provided an update of the status of its planned NDA submission for Marqibo ((vincristine sulfate liposomes injection).
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Government
Kennedy Ally Departs CDC Amid Leadership Shake-Up
February 23, 2026
·
1 min read
·
Annalee Armstrong
Approvals
Vanda Rebounds From Jet Lag Rejection With FDA Nod for Bipolar, Schizophrenia Drug
February 23, 2026
·
2 min read
·
Tristan Manalac
Legal
REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta
February 23, 2026
·
2 min read
·
Tristan Manalac
FDA
Makary, Prasad Under Fire as FDA Turmoil Reaches President Trump
February 20, 2026
·
6 min read
·
Heather McKenzie
